“Efficacy of Rifaximin in Diarrhoea Predominant Irritable Bowel Syndrome: A Placebo Controlled Clinical Trial”. Medicine Today, vol. 35, no. 1, Apr. 2023, pp. 44-48, https://doi.org/10.3329/medtoday.v35i1.64940.